Surufatinib (SULANDA®)

About HUTCHMED

HUTCHMED is a leading, innovation-driven biopharma focused on oncology and immunology, with a strategy of 'in China, for the world.' The company has successfully brought novel drugs like fruquintinib (ELUNATE®) to market in China and achieved its first global approval with Takeda. Its business model integrates discovery, development, manufacturing, and commercialization, supported by a deep pipeline of both internally discovered and in-licensed assets. HUTCHMED aims to become a global biopharmaceutical leader by advancing its pipeline through strategic global partnerships.

Therapeutic Areas